- Home
- CNTB vs RNTX Comparison
CNTB vs RNTX Comparison
Compare CNTB & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- RNTX
- Stock Information
- Founded
- CNTB 2012
- RNTX 2001
- Country
- CNTB United States
- RNTX United States
- Employees
- CNTB N/A
- RNTX N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- RNTX Health Care
- Exchange
- CNTB Nasdaq
- RNTX Nasdaq
- Market Cap
- CNTB 55.2M
- RNTX 44.2M
- IPO Year
- CNTB 2021
- RNTX N/A
- Fundamental
- Price
- CNTB $0.57
- RNTX $1.75
- Analyst Decision
- CNTB Strong Buy
- RNTX
- Analyst Count
- CNTB 1
- RNTX 0
- Target Price
- CNTB $8.00
- RNTX N/A
- AVG Volume (30 Days)
- CNTB 50.6K
- RNTX 27.6K
- Earning Date
- CNTB 03-31-2025
- RNTX 05-14-2025
- Dividend Yield
- CNTB N/A
- RNTX N/A
- EPS Growth
- CNTB N/A
- RNTX N/A
- EPS
- CNTB N/A
- RNTX N/A
- Revenue
- CNTB $26,033,000.00
- RNTX N/A
- Revenue This Year
- CNTB $997.61
- RNTX N/A
- Revenue Next Year
- CNTB N/A
- RNTX N/A
- P/E Ratio
- CNTB N/A
- RNTX N/A
- Revenue Growth
- CNTB N/A
- RNTX N/A
- 52 Week Low
- CNTB $0.55
- RNTX $1.61
- 52 Week High
- CNTB $2.66
- RNTX $7.42
- Technical
- Relative Strength Index (RSI)
- CNTB 26.20
- RNTX N/A
- Support Level
- CNTB $0.80
- RNTX N/A
- Resistance Level
- CNTB $0.84
- RNTX N/A
- Average True Range (ATR)
- CNTB 0.08
- RNTX 0.00
- MACD
- CNTB -0.02
- RNTX 0.00
- Stochastic Oscillator
- CNTB 6.34
- RNTX 0.00
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.